Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Literature DB >> 26559582

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Luis A Diaz, Dung T Le.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2015 PMID： 26559582 DOI： 10.1056/NEJMc1510353

Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245

Keyword Cloud
Cited

× No keyword cloud information.

83 in total

Review 1. Clinical implications of mismatch repair deficiency in prostate cancer.

Authors: Ramy Sedhom; Emmanuel S Antonarakis
Journal: Future Oncol Date: 2019-06-25 Impact factor: 3.404

Review 2. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology.

Authors: Antonia R Sepulveda; Stanley R Hamilton; Carmen J Allegra; Wayne Grody; Allison M Cushman-Vokoun; William K Funkhouser; Scott E Kopetz; Christopher Lieu; Noralane M Lindor; Bruce D Minsky; Federico A Monzon; Daniel J Sargent; Veena M Singh; Joseph Willis; Jennifer Clark; Carol Colasacco; R Bryan Rumble; Robyn Temple-Smolkin; Christina B Ventura; Jan A Nowak
Journal: J Mol Diagn Date: 2017-02-06 Impact factor: 5.568

3. Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium.

Authors: Brian C Willis; Emily A Sloan; Kristen A Atkins; Mark H Stoler; Anne M Mills
Journal: Mod Pathol Date: 2017-07-28 Impact factor: 7.842

4. Clinical Implications of Aberrant PD-1 and CTLA4 Expression for Cancer Immunity and Prognosis: A Pan-Cancer Study.

Authors: Jian-Nan Liu; Xiang-Shuo Kong; Tao Huang; Rui Wang; Wang Li; Qi-Feng Chen
Journal: Front Immunol Date: 2020-09-10 Impact factor: 7.561

5. Neutral Theory and the Somatic Evolution of Cancer.

Authors: Vincent L Cannataro; Jeffrey P Townsend
Journal: Mol Biol Evol Date: 2018-06-01 Impact factor: 16.240

6. Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management.

Authors: Jaydira Del Rivero; Lisa M Cordes; Joanna Klubo-Gwiezdzinska; Ravi A Madan; Lynnette K Nieman; James L Gulley
Journal: Oncologist Date: 2019-10-10

7. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.

Authors: Guillermo De Velasco; Youjin Je; Dominick Bossé; Mark M Awad; Patrick A Ott; Raphael B Moreira; Fabio Schutz; Joaquim Bellmunt; Guru P Sonpavde; F Stephen Hodi; Toni K Choueiri
Journal: Cancer Immunol Res Date: 2017-02-28 Impact factor: 11.151